ArticleInternational journal of fertility & sterility2026
Ethanol Sclerotherapy for Primary and Recurrent Endometrioma Improves
Article in International journal of fertility & sterility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Alcohol sclerotherapy has been shown to reduce endometrioma recurrence and improve ovarian response, including the number of retrieved oocytes and antral follicle count (AFC), compared with surgical cystectomy. This randomized clinical trial aimed to assess the effect of ethanol sclerotherapy on assisted reproductive outcomes in women with a history of primary and recurrent endometriomas. Materials and Methods: This single-blind randomized clinical trial included 80 infertile women aged 20-40 years with either primary or recurrent endometriomas. All participants underwent transvaginal ultrasound to evaluate endometrioma size, AFC, and serum hormone levels (anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH)) in the follicular phase. Patients were randomly assigned to the intervention group (n=40), receiving ethanol sclerotherapy, or the control group (n=40), receiving Dipherelin treatment. The sclerotherapy procedure involved cyst aspiration followed by ethanol instillation, with standard post-procedure care. Ovulation induction was performed, and subsequent reproductive outcomes, including pregnancy rates, were assessed in the same cycle. Results: The mean age of participants was 32.4 ± 4.75 years, and the mean endometrioma size was 41.45 ± 15.9 mm. Baseline characteristics and complications rates did not differ significantly between groups. Endometrioma recurrence was observed in 20% of patients in the intervention group within six months. Embryo quality was not significantly higher in the intervention group (P>0.05). Chemical pregnancy rates were 40% in the intervention group versus 20% in the control group (P=0.025), and clinical pregnancy rates were 32.5 versus 15% (P=0.040). Conception and implantation rates, however, did not differ significantly between groups. Conclusion: Ethanol sclerotherapy significantly improved clinical and chemical pregnancy rates compared to the control, suggesting that it may be a viable alternative to surgical cystectomy in selected patients, particularly those undergoing in vitro fertilization (registration number: IRCT20191206045629N1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.